These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 19172243)

  • 1. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.
    Cooper GJ; Young AA; Gamble GD; Occleshaw CJ; Dissanayake AM; Cowan BR; Brunton DH; Baker JR; Phillips AR; Frampton CM; Poppitt SD; Doughty RN
    Diabetologia; 2009 Apr; 52(4):715-22. PubMed ID: 19172243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairment.
    Lu J; Pontré B; Pickup S; Choong SY; Li M; Xu H; Gamble GD; Phillips AR; Cowan BR; Young AA; Cooper GJ
    Cardiovasc Diabetol; 2013 Jan; 12():28. PubMed ID: 23368770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy.
    Szwejkowski BR; Gandy SJ; Rekhraj S; Houston JG; Lang CC; Morris AD; George J; Struthers AD
    J Am Coll Cardiol; 2013 Dec; 62(24):2284-93. PubMed ID: 23994420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes.
    Gong D; Lu J; Chen X; Reddy S; Crossman DJ; Glyn-Jones S; Choong YS; Kennedy J; Barry B; Zhang S; Chan YK; Ruggiero K; Phillips AR; Cooper GJ
    Diabetologia; 2008 Sep; 51(9):1741-51. PubMed ID: 18636238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy.
    Farrant J; Dodd S; Vaughan C; Reid A; Schmitt M; Garratt C; Akhtar M; Mahmod M; Neubauer S; Cooper RM; Prasad SK; Singh A; Valkovič L; Raman B; Ashkir Z; Clayton D; Baroja O; Duran B; Spowart C; Bedson E; Naish JH; Harrington C; Miller CA;
    Heart; 2023 Jul; 109(15):1175-1182. PubMed ID: 37137675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat.
    Baynes JW; Murray DB
    Exp Diabetes Res; 2009; 2009():696378. PubMed ID: 19390595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copper chelation in patients with hypertrophic cardiomyopathy.
    Reid A; Miller C; Farrant JP; Polturi R; Clark D; Ray S; Cooper G; Schmitt M
    Open Heart; 2022 Feb; 9(1):. PubMed ID: 35169044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.
    Cooper GJ
    Drugs; 2011 Jul; 71(10):1281-320. PubMed ID: 21770477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regeneration of the heart in diabetes by selective copper chelation.
    Cooper GJ; Phillips AR; Choong SY; Leonard BL; Crossman DJ; Brunton DH; Saafi 'L; Dissanayake AM; Cowan BR; Young AA; Occleshaw CJ; Chan YK; Leahy FE; Keogh GF; Gamble GD; Allen GR; Pope AJ; Boyd PD; Poppitt SD; Borg TK; Doughty RN; Baker JR
    Diabetes; 2004 Sep; 53(9):2501-8. PubMed ID: 15331567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients.
    Suzuki K; Kato K; Soda S; Kamimura T; Aizawa Y
    Diabetes Obes Metab; 2004 May; 6(3):195-9. PubMed ID: 15056127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper chelation as a potential treatment for left-ventricular hypertrophy in type 2 diabetes.
    Bakker SJ; Navis G; Gans RO
    Diabetologia; 2009 Oct; 52(10):2244. PubMed ID: 19690830
    [No Abstract]   [Full Text] [Related]  

  • 12. Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments.
    Lu J; Gong D; Choong SY; Xu H; Chan YK; Chen X; Fitzpatrick S; Glyn-Jones S; Zhang S; Nakamura T; Ruggiero K; Obolonkin V; Poppitt SD; Phillips AR; Cooper GJ
    Diabetologia; 2010 Jun; 53(6):1217-26. PubMed ID: 20221822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals.
    Cooper GJ; Chan YK; Dissanayake AM; Leahy FE; Keogh GF; Frampton CM; Gamble GD; Brunton DH; Baker JR; Poppitt SD
    Diabetes; 2005 May; 54(5):1468-76. PubMed ID: 15855335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.
    Brown AJM; Gandy S; McCrimmon R; Houston JG; Struthers AD; Lang CC
    Eur Heart J; 2020 Sep; 41(36):3421-3432. PubMed ID: 32578850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indexation criteria of ventricular mass and predictive role of blood pressure and body composition.
    Ferrara LA; Vaccaro O; Cardoni O; Laurenzi M; Mancini M; Zanchetti A
    Am J Hypertens; 2005 Oct; 18(10):1282-7. PubMed ID: 16202849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consistency of left ventricular hypertrophy diagnosed by electrocardiography and echocardiography: the Northern Shanghai Study.
    Zhang W; Zhou Y; Bai B; Yu S; Xiong J; Chi C; Teliewubai J; Li J; Blacher J; Zhang Y; Xu Y
    Clin Interv Aging; 2019; 14():549-556. PubMed ID: 30880935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
    Bang CN; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Roman MJ; Køber L; Wachtell K; Devereux RB
    J Hypertens; 2013 Oct; 31(10):2060-8. PubMed ID: 23838656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between echocardiographic left ventricular mass index and electrocardiographic variables used in left ventricular hypertrophy criteria in Chinese hypertensive patients.
    Xie L; Wang Z
    Hellenic J Cardiol; 2010; 51(5):391-401. PubMed ID: 20876051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).
    Pouleur AC; Anker S; Brito D; Brosteanu O; Hasenclever D; Casadei B; Edelmann F; Filippatos G; Gruson D; Ikonomidis I; Lhommel R; Mahmod M; Neubauer S; Persu A; Gerber BL; Piechnik S; Pieske B; Pieske-Kraigher E; Pinto F; Ponikowski P; Senni M; Trochu JN; Van Overstraeten N; Wachter R; Balligand JL
    ESC Heart Fail; 2018 Oct; 5(5):830-841. PubMed ID: 29932311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass.
    Vitale G; Galderisi M; Pivonello R; Spinelli L; Ciccarelli A; de Divitiis O; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2004 Mar; 60(3):343-9. PubMed ID: 15009000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.